Research / Stocks / UTMD UTMD Nasdaq CIK 0000706698
UTAH MEDICAL PRODUCTS INC · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 8-K · Aug 31, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Filing → research 428 min
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT UTAH MEDICAL PRODUCTS INC's latest supported as-filed period reports revenue of $8.5M , 14.3% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity 70th Own-history percentile · N=20
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.57% · OPTIONAL
Operating cash generation 0th Own-history percentile · N=20
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 16.22% · OPTIONAL
Revenue growth 20th Own-history percentile · N=20
Method Yoy · gp.fundamentals.revenue
Raw value -14.31% · CORE
Inventory pressure 100th Own-history percentile · N=20
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 105.56% · OPTIONAL
Gross margin 0th Own-history percentile · N=20
Method Level · gp.fundamentals.gross_margin
Raw value 55.79% · CORE
Operating margin 15th Own-history percentile · N=20
Method Level · gp.fundamentals.operating_margin
Raw value 31.06% · CORE
R&D intensity 85th Own-history percentile · N=20
Method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Capital Allocation 4 evidence-backed dimensions Capex Intensity Inflecting Cash Generation Inflecting R And D Intensity Inflecting Sbc Intensity Stable [email protected] · 27 historical states · 88% confidenceCompany Direction 8 evidence-backed dimensions Capex Intensity Inflecting Cash Generation Inflecting Inventory Pressure Inflecting Margin Stable Profitability Deteriorating [email protected] · 27 historical states · 86% confidenceFinancial Quality 5 evidence-backed dimensions Cash Generation Inflecting Inventory Pressure Inflecting Margin Stable Profitability Deteriorating Sbc Intensity Stable [email protected] · 27 historical states · 88% confidenceGovernance Evidence 4 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 27 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Growth
UTMD -14.3
Peer median 9.2
Peer percentile 12th 76 valid peers · 86% coverage · -1.5 robust σ Inventory Pressure
UTMD 105.6
Peer median 72.0
Peer percentile 77th 79 valid peers · 90% coverage · +1.1 robust σ Profitability
UTMD 31.1
Peer median -6.7
Peer percentile 99th 83 valid peers · 94% coverage · +1.1 robust σ R And D Intensity
UTMD 1.8
Peer median 13.2
Peer percentile 1th 68 valid peers · 77% coverage · -0.8 robust σ Sbc Intensity
UTMD 0.8
Peer median 5.9
Peer percentile 5th 81 valid peers · 92% coverage · -0.7 robust σ Cash Generation
UTMD 16.2
Peer median -10.1
Peer percentile 89th 81 valid peers · 92% coverage · +0.7 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001096906-26-001210 11 governed changes · top 7 shown
Inventory Build Inventory built relative to revenue This cluster groups 2 independently calculated changes: Inventory increased 9.4%; Inventory / revenue moved 2284 bp higher.
2 evidence-backed components Margin Pressure Profitability margins compressed This cluster groups 2 independently calculated changes: Gross margin moved 43 bp lower; Operating margin moved 105 bp lower.
2 evidence-backed components 01
MEDIUM IMPORTANCE Operating Income 33TH HISTORICAL PCTL · N=3
Operating income decreased 17.1% Operating income changed -17.1% from the comparable as-filed period.
Why this ranks medium
Magnitude 13.69211514392991239048811014
Metric Family 24
Denominator Penalty 0
Historical Unusualness 0
Persistence Or Reversal 5
Significance Percent Of Revenue 6.413413061320201664907961074
Financial Statement Significance 7
Lowest Level false
Sample Count 3
Highest Level false
Largest Decline false
Largest Increase false
Reversal After Periods 0
Consecutive Direction Periods 4 [email protected] · [email protected]
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 1.57% +5.4% ↑ Capital expenditure $134,000 +3.1% ↑ Cash & equivalents $87.5M +0.0% ↑ Debt $0 — Free-cash-flow proxy $1.2M -58.1% ↓ Gross margin 55.79% +0.0% ↑ Interest expense $65,000 +0.0% ↑ Inventory $9.0M +3.2% ↑
ACTIVE TRACE Revenue UTMD · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 1.57% +5.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $134,000 +3.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $87.5M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Debt FY / 2025-12-31 $0 Comparable n/a Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 $1.2M -58.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 55.79% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense FY / 2015-12-31 $65,000 +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $9.0M +3.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 $2.7M +3.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 $1.4M -55.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 31.06% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2026-06-30 $154,000 +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
8-K Aug 31, 2026 Period Aug 31, 2026 0001096906-26-001326SEC ↗ 10-Q Aug 12, 2026 Period Jun 30, 2026 0001096906-26-001210SEC ↗ 8-K Jul 23, 2026 Period Jul 23, 2026 0001096906-26-001112SEC ↗ 4 Jul 1, 2026 Period Jun 29, 2026 0001733614-26-000003SEC ↗ 4 May 29, 2026 Period May 28, 2026 0001733614-26-000001SEC ↗ 10-Q May 12, 2026 Period Mar 31, 2026 0001096906-26-000767SEC ↗ 8-K May 4, 2026 Period May 1, 2026 0001096906-26-000685SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗